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Abstract
Epidemiology and innate immune monocyte function of
Staphylococcus aureus carriers and non-carriers in a medical
school community: A pilot study
Catherine M. Dailey and Barbara I. Kazmierczak
Section of Infectious Disease, Department of Internal Medicine
Yale School of Medicine, New Haven, 06510
Purpose: The purpose of this study was to examine host risk factors and measure
innate immune function in order to assess their potential associations with carriage of
Staphylococcus aureus (S. aureus). Nearly a third of individuals worldwide are carriers of
S. aureus. These bacteria usually exist as harmless commensal organisms of the skin or
mucosa, most frequently in the anterior nares. Some people are persistently colonized
with S. aureus while other people are intermittently or never colonized. If S. aureus gains
access to underlying tissues or to the bloodstream, it can cause serious life-threatening
infections, and colonization with S. aureus is a known risk factor for S. aureus infection.
Several factors have been associated with carriage such as diabetes, a compromised
immune system, obesity, eczema, and smoking tobacco. In addition, microbial genetics
and host defense mechanisms play a role in both colonization and infection. In this study,
we aimed to identify potential host factors related to S. aureus carriage.
Methods: Using serial nasal swabs over a 3-5 month period, we identified two
cohorts within our medical school community: those who were persistently colonized and
those who were never colonized with S. aureus. We assessed for risk factors for
colonization by administering questionnaires. We collected blood samples from a subset
of individuals within each cohort and isolated peripheral blood monocyte cells (PBMCs)

in order perform quantitative innate immune function experiments. Toll-like-receptors
(TLRs) are an integral part of the innate immune system. They are present on nasal
epithelial cells as well as immune cells such as PBMCs. We stimulated host PBMCs with
known TLR ligands and measured secretion of cytokines interleukin-8 (IL-8) and tumor
necrosis factor alpha (TNF-) by Enzyme-Linked ImmunoSorbent Assays (ELISAs).
Results: We enrolled 190 volunteer subjects from our medical school community
and 25% were carriers of S. aureus after a single swab. Among those who completed all
swabs, we identified 33 (33%) who were persistently colonized and 69 (68%) who were
persistently not colonized. We did not identify any host risk factors significantly
associated with persistent colonization. We noted a decreased secretion of both IL-8 and
TNF-α by PBMCs from persistent carriers. IL-8 secretion was significantly diminished
after stimulation with FSL-1, LTA, Agr (+) S. aureus, and Agr (-) S. aureus, as shown by
non-parametric two-sided t-test analysis (P <0.05). Although there was an observed
decrease in TNF-α secretion by PBMCs from persistent carriers, none of the differences
reached statistical significance.
Conclusion: One third of subjects who completed all swabs were found to be
persistent carriers; and thus persistently at increased risk of S. aureus infection. We found
a trend in which persistent carriers had a diminished innate immune response evidenced
by less IL-8 and TNF-α secretion following TLR stimulation when compared to noncarriers. In particular, we noted decreased IL-8 secretion after stimulation with ligands
known to have lipoprotein properties, suggesting a possible underlying dysfunction in
TLR-2. Further investigation into the significance of our findings is warranted.
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Introduction
Staphylococcus aureus: benign and pathogenic
Staphylococcus aureus (S. aureus) usually is a harmless commensal bacterium of
the skin and mucosa of humans and some animals (1). It has a predilection for human
colonization because of its enhanced capacity to extract iron nutrients from human
hemoglobin in comparison to the hemoglobin of other animals, such as the mouse,
making humans an excellent source of both benign and pathogenic organisms (2). The
most frequent site of colonization, or carriage, is the anterior nare. The anterior nares
contain keratinized squamous epithelium and hair follicles but are devoid of cilia and
subepithelial glands (3). S. aureus binds preferentially to the keratinized epithelial cells
(4) and depends on surface mucin secreted by the host for colonization (5). Other
anatomical sites for S. aureus colonization are the perineum, gastrointestinal tract,
axillae, vagina, pharynx, or damaged skin surfaces (6). Although S. aureus is known to
colonize several locations, the relevance of extra-nasal carriage is not well known (1).
When there is a breach of the epithelial or mucosal barrier, staphylococci gain
access to adjoining tissues or the bloodstream and can potentiate infection. Both host and
bacterial factors affect the progression of an infection because there is a complex
interplay between S. aureus virulence determinants and host defense mechanisms (7). As
a species within the genus Staphylococcus, S. aureus is the most human-pathogenic and
does not require a predisposing condition or an immunosuppressive setting in which to
proliferate. In other words, infected patients can be generally healthy at baseline. S.
aureus can cause both mild and life-threatening infections ranging from folliculitis and
furunculosis to bacteremia, sepsis, deep tissue abscesses, pneumonia, osteomyelitis, and
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infective endocarditis. The presence of a foreign material, such as an indwelling catheter,
increases susceptibility to infection in an immunocompetent host (7). S. aureus ranks
second as the cause of nosocomial blood infections, and such infections increase
morbidity, mortality, length of stay, and health care costs (1). The growing threat of
resistant organisms adds additional complications. The associated clinical and social costs
are estimated at $6–9 billion per year in the United States alone, making S. aureus a
pressing health care issue (8).

S. aureus carriage and infection are interconnected
The link between carriage and infection was first noted in 1931. Subsequently,
there has been considerable effort to better understand the relationship between carriage
of S. aureus and S. aureus infection. It is now widely accepted that colonization with S.
aureus is linked to an increased risk of infection, including life-threatening ones (9) and
that the strain that establishes colonization is often the same one that causes infection in
the host (5). Persistent carriers are known to have higher loads of S. aureus, and hence
are at particular risk for infection (6).
The association of carriage and infection is important in the hospitalized setting
where there are resistant bacteria, such as methicillin-resistant S. aureus (MRSA), which
are more challenging and costly to treat. Such challenges have influenced formation of
hospital policies across the world. Healthcare workers have been found to be a source and
means of transmission or cross-infection between patients (10). Identification of
asymptomatic carriers with active surveillance and placing them under contact
precautions are standard practices. In some countries, such precautions are mandated
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since colonized patients have been found to be the chief source of S. aureus within
hospitals (11).
Those who are colonized with S. aureus have a threefold increase in the risk for
nosocomial infection (1). Von Eiff et al. has shown a particularly increased risk of
infection for certain colonized populations, such as post-surgical, peritoneal dialysis, and
hemodialysis patients; and they have noted that catheter related infections are the most
common cause of S. aureus blood infections (5). Once carriers are identified, treating
with nasal mupirocin leads to a decrease in nosocomial infections in some populations
(12) and elimination from the nares and other parts of the body such as the hands (13).
Unfortunately, eradication has not been definitively shown to affect infection rates (6),
and such treatments may allow for recolonization of the epithelium by the same or a
different strain (14) or even make colonization more permissible (15).

Identifying S. aureus
Most studies of S. aureus colonization of humans obtain swab samples from the
anterior nares for culture, which are then evaluated for S. aureus. S. aureus was first
discovered by surgeon Sir Alexander Ogston in 1880 in Aberdeen, Scotland after he
examined pus from post-operative wound infections under a microscope. The organisms
he saw appeared like a cluster of grapes and he called his finding “staphyle,” which is
Greek for “a bunch of grapes.” S. aureus bacteria appear as gram-positive cocci situated
in clusters or pairs. In 1884, scientist Rosenbach grew the same bacteria from pus and
observed its yellow-orange pigment and he called it “aureus,” which is Latin for
“gold”(1,16). These fundamental properties that were observed over a hundred years ago
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are still considered defining features of S. aureus. In addition to having a distinct shape
and color, S. aureus is among the population of bacteria that can induce hemolysis.
Hemolysis is the capacity to break down red blood cells, which S. aureus uses to extract
iron, a vital nutrient (2). The microscopic and macroscopic appearances of S. aureus and
its hemolytic property serve as laboratory indicators of its presence and can be used in
devising a method for identification.
Studies have identified three phenotypes of carriage: persistent, intermittent, and
non-carriers (17). Nouwen et al. found that the positive predictive value of two
consecutive positive swab cultures was 79% in determining persistent carriage status, but
the best model for determining persistent carriage was two positive swab cultures plus
quantitative evaluation of the S. aureus culture (positive predictive value 93.6%). They
found that one negative screening virtually excluded the persistent carriage phenotype,
and no person whose first two cultures were positive was found to be of the non-carrier
phenotype. In order to distinguish non-carriers from intermittent carriers, their findings
suggest that at least seven cultures are necessary (18). In order to develop a reliable
system for identification of different carrier phenotypes, one must carefully consider how
many swabs to obtain and how each cohort is distinguished.

Prevalence of S. aureus carriage
Over two billion individuals worldwide are colonized with S. aureus (19). The
National Health and Nutrition Examination Survey (NHANES) has been administered
continuously since 1999 to a nationally representative sample of civilian and noninstitutionalized people in the United States. A single swab test along with survey data
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regarding S. aureus nasal carriage has been collected since 2001. Gorwitz et al.
investigated the NHANES data from 2001-2004 and found that the prevalence of
colonization decreased from 32.4% to 28.6% over that time period, and colonization of
MRSA increased from 0.8% to 1.5%. It is unclear, however, if such changes represent
trends or short term modulations (9).
Colonization is influenced by environmental factors such as age, health, economic
status, and country of residency - colonization is higher in developed countries. In the
United States, carriage of S. aureus ranges from 26-32% of people at any given time, and
nearly 20% of people are persistently colonized (1). In developed countries,
approximately 20% of people are persistent carriers of S. aureus, 30% are intermittent
carriers, and 50% are non-carriers (9) (20).
Persistent carriers have particular characteristics that impact their risk for serious
infections. Those who carry MRSA are most often persistent carriers (21). Persistent
carriers have higher loads of S. aureus (21), and usually carry a single strain, while
intermittent carriers can carry different strains over time suggesting a different
mechanism of colonization for those two phenotypes (22). Children, especially infants,
have high persistent carrier rates, but values level off in adulthood as people change their
carrier state between the ages of ten and twenty (6).

Factors associated with S. aureus carriage
There are various medical conditions shown to promote increased S. aureus
carriage rates, including diabetes; obesity; end stage renal disease; hemodialysis;
peritoneal dialysis; HIV infection; compromised immune system; IV drug use; eczema;
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psoriasis; history of smoking, and history of stroke (6) (1) (9) (17) (23). Analysis of the
NHANES data from 2001-2004 identified an association between MRSA colonization
and recent healthcare exposure, diabetes, old age, and poverty (9). There has been no
relation found between carriage and seasonality, temperature, or humidity (6). Some
activities have been associated with increased carriage rates, such as river rafting;
football; and pig farming. The most common mode of transmission is hand-to-hand
contact (6), and, not surprisingly, nasal carriage is strongly associated with hand carriage.
Interestingly, most mothers carry the same strain as her children, revealing the
significance of transmission within cohort populations.
The host immune system employs various barrier defense strategies against S.
aureus including mechanical clearance and antimicrobial secretions (24). Important
components of nasal secretions that mediate inflammation are defensins, lysozymes,
lactoferrin, and mucin (25). Carriage is increased in hosts whose nasal secretions are
deficient in antimicrobial activity (26). The nasal mucosa also releases complement and
cytokines (27). Molecules such as C-reactive protein (CRP) and cytokines such as tumor
necrosis factor alpha (TNF-α), Interleukin-8 (IL-8), Interleukin-6 (IL-6), and Interleukin1β (IL-1β) have been identified as host mediators during S. aureus colonization (28).
Although it is not known, one might surmise that host deficiencies in these immunologic
molecules would likely facilitate the carrier phenotype.
Persistent carriers and persistent non-carriers who were inoculated with identical
mixtures of S. aureus had differing colonization results suggesting the importance of
genetic host factors (14). It has been postulated that the presence of the histocompatibility
antigen HLA-DR3 may be a predisposition to nosocomial S. aureus infections (29).
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Polymorphisms of various genes have also been liked to nasal carriage, such as the Fc
fragment of IgG, the human glucocorticoid receptor (30), polymorphic variations in the
vitamin D receptor gene in patients with type I diabetes (31), IL-4 (C542T genotype), and
the human complement cascade activator serine protease C1 inhibitor (C1INH V480M)
(15). Emont et al. has shown that the IL-4 C-allele is associated with nasal carriage, and
they observed decreased host production of IL-4 and mucin. Some CRP gene haplotypes
may be associated with resistance to colonization (23). Gonzalez-Zorn et al. have
identified CFTR and TLR-2 as genetic host factors that may protect the system against
carriage of S. aureus in animal models (32), and one might postulate that a defect in these
genes may diminish the protection. Despite many varied investigations, a significant
association between carriage and a particular genetic host factor has yet to be identified.
Bacteria factors also play a role in colonization in concert with host factors. It has
been suggested that there may be a bacteria-induced local immunosuppression because
nasal fluid from carrier hosts is defective in killing carrier strains compared to non-carrier
strains (24). Host IL-1 is secreted as an immunologic mechanism to avoid colonization,
but it seems that are strains of S. aureus that are less susceptible to IL-1 and can maintain
a competitive advantage in their microenvironment by evading the host immune response
(24). Nitric oxide (NO) is a broad-spectrum host mechanism for resistance to
microorganisms since it disrupts oxygenation, but S. aureus employs its own strategies to
combat those of the host. S. aureus can persist and replicate using hypoxic/anaerobic
metabolism. Unlike for any other staphylococcal species, lactate dehydrogenase (LDH) is
induced by NO in S. aureus, providing a mechanism for survival. If this genetic
mechanism for survival against NO is disrupted, S. aureus is less virulent (19).
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Colonizing and invasive strains of Methicillin-Susceptible S. aureus (MSSA) and
Methicillin-Resistant S. aureus (MRSA) have been be categorized through multilocus
enzyme electrophoresis, pulsed-field gel electrophoresis, multilocus sequence typing
(MLST), and amplified fragment length polymorphism (AFLP). They can be categorized
into five distinct clusters: CC8, CC30, CC5, CC22, CC45; or three major and two minor
clusters: I, II (CC30), III (CC45), IVa, IVb. Clusters II and III (CC30 and CC45) account
for nearly half of all carriage isolates and have evolved to colonize humans particularly
well. There does not seem to be clear distinctions between colonizing and pathogenic
organism between the clusters. Acquisition of the mecA regulon, which bestows
methicillin resistance, can occur in all cluster populations. Any S. aureus genotype has
the capacity to colonize and transform into a human pathogen. Thus, it is hypothesized
that microbial accessory genes, apart from the core genome, may affect the pathogenic
potential of S. aureus (1). Agr, a S. aureus accessory regulator virulence gene, is
functional in the majority of S. aureus bacteria, but it is not a necessary virulence gene
since agr-defective S. aureus mutants maintain the capacity for infection. It has been
shown that 9% of host carriers are actually harboring an agr-defective organism (33).
Further investigation into microbial accessory genes is warranted in order to determine
which aspects of microbial genetics play a role in colonization and infection.
Colonization is a dynamic process that involves competition between different
microorganisms within the context of the host immune response. An epidemiologic study
with healthy human volunteers has shown that colonization with a species of S.
epidermidis that secretes serine protease Esp will lead to elimination of S. aureus nasal
colonization. This study identifies a particular circumstance in which the local
microbiome plays a significant role affecting the presence of certain bacteria (34). In
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children, there is an inverse correlation between the colonization of S. aureus and the
colonization of Streptococcus pneumoniae (S. pneumoniae), and it has been shown that
he presence of S. aureus or S. pneumoniae can facilitate the invasion of a Haemophilus
influenza population (35), indicating the importance of inter-organism dynamics (36).
When a resident bacteria population occupies a niche, other bacteria do not seem to have
the capacity to replace the resident population. Margolis et al. have studied the ecology of
nasal colonization in a neonatal rat model and have shown that bacteria in the nasal
epithelium reach a steady state within forty-eight hours regardless of inoculum dose,
which lasts for at least three days. They observed that S. aureus strains required the host
to have no other S. aureus bacteria present in order to colonize effectively (1). It is
thought, therefore, that any disruption of the local microbiome, such as with antibiotic
use or nasal sprays, may significantly impact S. aureus colonization.

The innate immune system and S. aureus
Carriage elicits an immune response that can be identified by seroconversion after
colonization (37). The manners in which S. aureus evokes a host immune response
remain topics of continued research. The primary cellular host defense against S. aureus
infection are polymorphonuclear leukocytes (2), but the innate immune system plays an
important role early in exposure. The innate immune system has an integral role at the
interface between the host and its external environment. Pattern recognition receptors
(PRRs) are expressed on the surface of effector immune cells and other cell types that are
first to encounter pathogens, such as surface epithelia. PRRs induce endogenous signals
allowing for effective combat against microbial invaders. PRRs have evolved to
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distinguish pathogenic organisms, and one set of receptors for pathogen-associated
molecular patterns (PAMPs) are Toll-Like-Receptors (TLRs) (38).
There have been eleven human and thirteen mouse TLRs identified. Each TLR
identifies a conserved feature of a pathogenic organism. For example, TLR-4 recognizes
LPS on gram-negative bacteria and TLR-9 recognizes bacterial DNA (39). Each TLR is a
type I transmembrane receptor possessing an extracellular leucine-rich repeat and a
cytoplasmic Toll/IL-1 receptor homology domain. When a ligand binds a TLR, the
adaptor molecule MyD88 is recruited to the Toll/IL-1 receptor domains, which confers a
series of intracellular signaling. MyD88 is essential for TLR signaling, and its
downstream effect is activation of transcription factor NFkB, which permits the
transactivation of proinflammatory cytokine genes (40).
Gram-positive bacteria, such as S. aureus, are recognized by TLR-2, but the nature
of the TLR-2 PAMP was under debate until recently. It was thought that peptidoglycan
(PGN) was a potential TLR-2 ligand, but instead it was found that PGN binds
Nod2/Nod1 receptors. Other PAMPs such as LPS, LTA, lipomannans, and
lipoarabinomannans have been associated with TLR-2 stimulation (39), but such a variety
of ligands seemed dubious given the pattern principles underlying TLRs (41). It has been
shown that the lipoprotein fraction isolated from S. aureus specifically activates TLR-2
(42) and that lipoprotein is necessary to invoke a cytokine response (35) (43) (41).
Bacterial variants that lack lipoproteins have been found to evade immune recognition
and cause particularly lethal infections (44). Adequate detection and response by the host
innate immune system is paramount in keeping colonizing bacteria at bay, and it appears
that lipoproteins are vital for TLR-2 recognition.
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Bacterial lipoproteins can be diacylated or triacylated. Synthetic lipoproteins, such
as Pam3Cys and Pam2CSK4, have been used experimentally to mimic the proinflammatory response to lipoproteins. These experiments led to a longstanding model
that triacylated lipopeptides from gram-negative bacteria stimulate TLR2/TLR1
heteromers and that diacylated lipopeptides from gram-positive bacteria stimulate
TLR2/TLR6 heteromers (45). Tawaratsumida et al. have since isolated the activating
TLR-2 lipoproteins identifying several molecules including diacylated lipoproteins,
quinol oxidases, and ATP-binding cassette transporters, such as the iron regulated ATPbinding cassette, SitC. (46).
It turns out that TLR-2 senses a pattern of abundant bacterial ABC transporter
substrate-binding lipoproteins (41) as well as buried triayclated lipoproteins on the
bacterial cell wall (47). S. aureus infection in mice that are deficient in TLR-2 or MyD88
results in increased mortality, disease severity, bacterial burden, and impaired cytokine
production, suggesting the importance of an intact TLR pathway in the fight against S.
aureus (48). Strict mouse models of S. aureus infection have limitations, however, and
future studies in transgenic mouse models may lead to more correlative findings
regarding human TLR-2 and its impact on the host immune response to S. aureus
colonization and infection (2).
In vitro experiments have shown that TLR-2 is upregulated by exposure to S.
aureus (49). Incubation with escalating doses of S. aureus results in a dose dependent
increase of pro-inflammatory cytokines TNF-α and IL-8 (49); IL-8 secretion is TLR-2
dependent in human keratinocytes (50). Expression of TLR-2 is delayed by up to four
hours by carrier strains of S. aureus compared to non-carrier strains (3) resulting in a
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possible local immunosuppressive mechanism for colonization. In their studies
examining the immunomodulatory factors of atopic eczema, Mempel showed that TLR-2
expression is distributed unevenly within the layers of the skin with increased density in
the basal epidermis, suggesting a mechanism for atopic dermatitis in which colonization
remains benign until the barrier is disturbed. Once bacteria are exposed to the high
concentration of TLR-2 in the deeper skin layers, the immune response is exacerbated
(50). In vitro experiments with human cells have offered some insights into the
relationship between S. aureus and TLR-2, but many of the secrets regarding S. aureus
and its complex dance with the host immune system remain unknown.
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Specific Aims
There are environmental, medical, and genetic host factors that affect Staphylococcus
aureus colonization. We are interested in looking at two populations of S. aureus carriers:
persistently colonized and persistently not colonized individuals. Identification of the two
target populations of S. aureus carriers who represent the extreme phenotypes of
colonization provides an opportunity for comparison. Certain environmental factors that
occur in our healthy population may be more represented in those who are persistently
colonized, such as children in day care, hospital exposure, and public gym exposure.
Such factors may play a role because of the skin-to-skin transmission of S. aureus.
Medical factors such as diabetes and current tobacco use also may be over-represented in
our persistent carrier group. Other studies have demonstrated this association, possibly
due to the effect of chronic systemic inflammation of the immune system’s ability to
clear colonizing organisms. It is also possible that the function of the innate immune
system may be impaired in those who are persistently colonized. Faced with S. aureus in
the anterior nares, an impaired immune system may not effectively clear the organism.
Epithelial cells expressing Toll-Like-Receptors (TLRs) in the anterior nares serve as
innate immune system defenses triggering an immunologic cascade. Many other cell
types, such as monocytes, express TLRs as a surveillance mechanism for invading or
colonizing organisms. Since experiments with epithelial cells are less common and
technically more complicated, peripheral blood monocyte cells (PBMCs) are a reasonable
alternative for immunologic testing, and this was our avenue of exploration. If there were
dysfunction in a particular TLR pathway, we would expect to observe a decrease in proinflammatory cytokine production, specifically Interleukin-8 (IL-8) and tumor necrosis
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factor alpha (TNF-α), after stimulation with corresponding TLR pathogen-associated
molecular patterns (PAMPs). We aim to study the PBMC function as it relates to TLR
stimulation. If the function of the innate immune system is a significant factor in
colonization status, we may see a difference in cytokine response between our two cohort
groups.

1) Identify a persistent S. aureus carrier group and a persistent non-carrier group
comprised of healthcare workers and students within this institution’s community.

2) Examine questionnaire data from the identified groups and perform statistical analysis
to assess for risk factors associated with persistent non-carriers or persistent carriers.

3) Isolate peripheral blood monocyte cells (PBMCs) from the identified groups and
assess innate immune system function by stimulating with TLR ligands and measuring
secretion of IL-8 and TNF-α in order to determine if there is a difference in innate
immune function between the identified groups.
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Materials and Methods
Recruitment
Protocol for this study and its associated documents was approved by the local
Institutional Review Board and Human Investigation Committee (HIC #0805003891).
Methods for recruiting human subjects for consent and participation included the
following: informative postings on bulletin boards around our institution’s medical
school campus; e-mail solicitation of members of our institution’s medical community;
informative meetings organized for specific medical community populations; and
personal encounters with members of the community. Informed consent was obtained for
each participant. The personal information of all subjects was stored in a password
protected, secured computer. Enrollment in this study was by volunteer only; individuals
were not compensated for their participation.

Identifying target groups
At enrollment, subjects completed a questionnaire and provided a nasal swab sample. The
subject repeated the questionnaire and nasal swab in 4-6 weeks increments for a total of
four encounters over approximately 3-5 months. Follow-up appointments were scheduled
using contact information provided by the participant. The presence or absence of S.
aureus from the nasal swab was determined for each subject after each encounter.
Questionnaire data were collated. Subjects were noted to be positive (presence of S.
aureus) or negative (absence of S. aureus). A pattern was identified for each subject after
the second encounter in which a subject had either the same or a different result
compared to the prior swab. Those subjects who had different results were excluded from
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the study. Patterns were re-assessed after each encounter for each subject. Those subjects
who maintained a pattern of either all positive or all negative results continued to be
included in the study. After four encounters were completed, subjects were contacted to
schedule a fifth appointment at their convenience to donate approximately 60mL of blood
anonymously, offer two nasal swabs, and repeat the questionnaire. After preliminary
analysis of results from blood sample studies, it was noted that some samples were
extreme outliers when compared to others. The subjects associated with these samples
were identified and contacted to schedule a sixth appointment at their convenience to
donate another blood sample, nasal swab, and repeat questionnaire.

Questionnaire
The questionnaire was developed and formatted by this author and Barbara Kazmierczak
M.D., Ph.D. The questionnaire included questions about demographics and risk factors
thought to be associated with S. aureus colonization or infection. It also inquired about
settings in which subjects were in contact with hospitalized patients. The same
questionnaire was administered at each subject encounter. The demographics section was
usually completed only once. The data from the questionnaires were put into a digital
spreadsheet using Microsoft Access and Microsoft Excel. (See Supplemental
Material for example questionnaire).
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Nasal swab
Nasal swabs were obtained using sterile Starswab II (Starplex Scientific Inc.; Ontario,
Canada). Each packaged unit contained two swabs attached to a plastic top and a capped
sheath in which to put the swabbed sample. A member of the study team collected each
sample. Holding the capped end, the two swabs were inserted into the anterior portion of
one nostril and were rotated against the walls of the inner nose four times around. The
swabs were then inserted into the anterior portion of the other nostril and rotated in the
same fashion. The swabs were then placed in the labeled sheath for transport. Samples
were kept at room temperature. At the fifth encounter, an additional swab was collected
for frozen storage: the anterior nares were swabbed as described above, and swabs were
cut in a sterile fashion into a sterile tube. These samples were stored at -20 degrees
Celsius.

Plate culture
Nasal swabs were plated onto Mannitol Salt Agar (MSA) (Remel; Lenexa, KS) and
Blood Agar: TSA with 5% Sheep Blood (BSA) (Remel; Lenexa KS) within 12-14 hours
after collection. Swabs were removed from the sheath and spread onto one-third of each
plate. A sterile loop was used to spread the sample into the second third of the plate. The
second portion was then spread to the third portion of the plate with a sterile loop. Plates
were incubated at 37 degrees Celsius for 24-48 hours or 30 degrees Celsius for 72 hours.
Observations of color, scent, and hemolysis of were recorded for each plate. Swab
samples and culture plates were discarded into the appropriate biohazard containers.
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Identifying Staphylococcus aureus
Colonies that appeared bright yellow on the MSA plate and colonies that appeared
golden/yellow-gray on the BSA plate were suggestive of S. aureus. The golden BSA
colonies were evaluated using the Staphaurex* test (Remel; Lenexa, KS) according to the
manufacturer’s instructions, which has positive predictive value of 99.6% and negative
predictive value of 99.8% for identification of S. aureus. Yellow colonies on the MSA
plate were not evaluated directly by Staphaurex*. When identified, a few of the yellow
MSA colonies were sub-cultured from the MSA plate onto a fresh BSA plate with a
sterile loop and were incubated as described above. Golden colonies from the subcultured BSA plates were then evaluated by Staphaurex* as described above. Once a
sample revealed the presence of S. aureus, further evaluation of other plate samples was
discontinued. When there was suspicion for the presence of S. aureus but the
Staphaurex* test was negative, further work-up was pursued. For some samples, a
catalase test was administered with 3% hydrogen peroxide. If bubbles formed, the sample
was noted to be catalase positive with the possibility of S. aureus upon further testing. If
no bubbles formed, sample was noted to be catalase negative and further testing was not
done. For some samples, Gram Stain (Sigma Diagnostics, Inc.; St. Louis, MO) was
performed on suspected samples followed by a Coagulase Plasma test (Remel; Lenexa,
KS) of the identified gram positive cocci colonies. Plates with a negative Staphaurex*
test, a very low suspicion for S. aureus, or a negative Coagulase Plasma test were noted
to be negative for S. aureus. Each positive S. aureus sample was cultured in liquid LB
media and stored at -80 degrees Celsius in a 30% concentration of 50% glycerol. The
plate processing and identification of S. aureus was performed by this author and other
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members of the Kazmierczak lab. (See Supplemental Material Figure 1 for schematic of
microbial analysis).

Blood Draw
Using standard phlebotomy techniques, a 21 gauge Safety-Lok (BD Vacutainer;
Franklin Lakes, NJ) needle with plastic applicator (BD Vacutainer; Franklin Lakes, NJ)
was used to collect approximately 60mL of blood into 6-7 blood collection tubes
containing 143 USP units sodium heparin (BD Vacutainer; Franklin Lakes, NJ).
Samples were processed for peripheral blood monocyte cells (PBMCs) within two hours
of collection. The blood draws were performed by this author or Barbara Kazmierczak
M.D., Ph.D.

Peripheral Blood Monocyte Cell (PBMC) Isolation
Blood was mixed 1:1 with Gibco PBS (Invitrogen; Grand Island, NY) and separated
into 30mL aliquots. Approximately 20-30 mL of the sample was layered carefully on top
of 10.0mL Ficoll-PagueTM PLUS (GE Healthcare Biosciences Piscataway, NJ) in as
many conical tubes as necessary. Samples were centrifuged (Sorvall Legend RT) at
1800 rpm for 20 minutes at room temperature with the brake off. Glass pasteur pipettes
were used to collect the middle, opaque layer containing mononuclear leukocytes
(MNLs). The collected sample was transferred to a conical containing 10mL Gibco
RPMI Medium 1640 (Invitrogen; Grand Island, NY). Additional RPMI was added for a
total volume 40mL per tube. Samples were centrifuged at 1300rpm for 10 minutes at 4
degrees Celsius. The supernatant was discarded. The pellet was washed twice with 15mL
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chilled RPMI at 1300rpm for 10 minutes at 4 degrees Celsius. For some samples, there
appeared to be an increased amount of red blood cell contaminants. For those samples,
1mL red blood cell lysing buffer (Sigma Aldrich; Steinheim, Germany) was added
between the two washes and incubated for 5 minutes. 15ml of RPMI was then added to
neutralize the reaction. This was followed by the second wash. After two washes, the
pellet was re-suspended in 2mL warm culture medium, which consisted of Gibco RPMI
Medium 1640 (Invitrogen; Grand Island, NY) with 20% human serum (Lonza Group
Ltd.; Basel, Switzerland) and 1% Penicillin/Streptomycin. Cells were counted and PBMC
concentration was determined for each sample. PBMC isolation and stimulation
experiments were performed by this author and other members of the Kazmierczak lab.

Stimulation of PBMCs
The PBMC isolate was diluted to a concentration of 2 x 106 cells/mL by adding the
appropriate volume of culture media. 106 cells were added to each well of a 24-well plate
(Costar 3526 Corning Inc.; Corning, NY). Plates were cultured at 37 degrees Celsius in
5% CO2 for 2 hours. Plates were washed twice with 0.5mL/well RPMI in order to remove
non-adherent cells. Monocytes remained adherent, and cells were confirmed by
microscopy. Ligand preparations were added 0.5mL/well in concordance with our
experiment template. Control wells contained only culture media. The following ligands
were used: Muramyl dipeptide (MDP) (InvivoGen; San Diego, CA) 10ug/mL, which is a
minimal bioactive peptidoglycan motif NOD 2 ligand; Ultra pure E. coli K12 LPS
(InvivoGen; San Diego, CA) 100ng/mL, which is a purified lipopolysaccharide from E.
coli K12 strain and TLR-4 ligand; Purified LTA-SA (InvivoGen; San Diego, CA)
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1ug/mL, which is a purified lipoteichoic acid from S. aureus and TLR-2 ligand; ST-FLA
(InvivoGen; San Diego, CA) 1ug/mL, which is a purified Flagellin from S. typhimurium
and TLR-5 ligand; Pam3CSK4 (InvivoGen; San Diego, CA) 1ug/mL, which is a
synthetic bacterial lipoprotein and TLR-2/TLR-1 ligand;. FSL-1 (InvivoGen; San Diego,
CA) 0.1ug/mL, which is a synthetic diacylated lipoprotein and TLR-2/TLR-6 ligand;
Agr(+) S. aureus thawed preparation (Barbara Kazmierczak M.D., Ph.D lab; New Haven,
CT) 107cells/mL; Agr(-) S. aureus thawed preparation (Barbara Kazmierczak M.D., Ph.D
lab; New Haven, CT) 107cells/mL. Plates were incubated at 37 degrees Celsius in 5%
CO2. Supernatants were collected in a sterile fashion and stored at -80 degrees Celsius.
Some wells were re-stimulated with an aforementioned ligand according to our
experiment protocol such that cells initially stimulated with LPS or MDP were restimulated with LPS or LTA. Plates were incubated for 24 hours at 37 degrees Celsius in
5% CO2. Supernatants were collected in a sterile fashion and stored at -80 degrees
Celsius.

Enzyme-Linked ImmunoSorbent Assays (ELISAs)
Supernatants that were collected from the PBMC stimulation experiments were used to
perform ELISAs specific for detecting human interleukin-8 (IL-8). Human Interleukin-8
ELISA Ready-SET-Go! Kit (eBioscience; San Diego, CA) and Human TNF-α ELISA
MAX Set Standard kit (BioLegend, Inc.; San Diego, CA) were used according to the
manufacturer’s instructions. Samples for the IL-8 ELISAs were diluted 1:500. Samples
for the TNF-α ELISAs were diluted 1:50 for Agr(+), Agr(-), Flagellin, and LPS samples
and diluted 1:10 for all other samples. Nicole Jackson (Yale College ’11) and Carla
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Weibel aided in the troubleshooting and protocol development of both the IL-8 and TNFα ELISAs as well aiding in acquisition of data from the supernatant samples. This author
and other members of the Kazmierczak lab also performed ELISA experiments on
samples using the developed protocols.

Statistical methods
Chi squared or Fisher’s exact test was used to test for significant associations for
categorical variables obtained from the questionnaire. Two-tailed t-test was used in
comparing mean age for each group. In the instances where there was no response for a
given categorical variable on the questionnaire, the missing data was omitted from the
analysis if its frequency was ≤ 3%. Duplicate ELISA data was averaged for each subject
and corrected by subtracting the control value (media only well). Two-tailed MannWhitney test was used to test for significant differences in cytokine levels between
carriers and non-carriers for each PBMC stimulation scenario. One-way ANOVA
Kruskall-Wallis test with Dunn’s comparison post-test was also used to test for
significance in the IL-8 dataset. GraphPad Prism 5 software package was used for
statistical calculations. A value P < 0.05 was considered statistically significant.
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Results
Prevalence: Nasal carriage of S. aureus
A total of 190 volunteer subjects enrolled in our study and donated a nasal swab for
culture. After the first nasal swab, 48 (25%) subjects were carriers of S. aureus while 142
(75%) were not (Figure 1). As swabs were collected, subjects were deliberately not
followed if their colonization status changed. After the fourth swab was obtained, we
identified 102 individuals who either remained culture positive for each swab or culture
negative for each swab, and we designated these cohorts as persistently colonized or
persistently not colonized, respectively. Of the 102 individuals who donated four swabs,
33 (33%) were persistently colonized and 69 (68%) were persistently not colonized. A
total of 21 subjects switched colonization statuses during the 3-5 month period in which
the first four swabs were collected. A change from non-carrier to carrier was most
common (data not shown). The blood draw occurred several months to a year after the
four swabs were obtained. We lost 43 individuals to follow-up and there were 3 failed
blood draw attempts. Of the 102 subjects whose colonization status was identified, 21
persistent carriers donated blood, and 35 persistent non-carriers donated blood.
Interestingly, 3 subjects changed their colonization status by the time the blood draw
occurred as evidence by the fifth culture swab obtained during the blood donation. One
subject switched from carrier to non-carrier while two subjects switched from non-carrier
to carrier. These individuals were excluded from cytokine analysis.
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FIGURE 1: Experimental design and subject count during course of this study
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TABLE 1: Characterization of cohort populations after the first nasal swab

Non-carriers
N = 142 (75%)

Carriers
N = 48 (25%)

P value

Male

63 (44%)

25 (52%)

0.4039

a

Female

79 (56%)

23 (48%)

Hispanic

8 (6%)

1 (2%)

0.5033

b

Non-Hispanic

116 (82%)

39 (81%)

No Response

18 (12%)

8 (17%)

White

95 (67%)

37 (77%)

0.2831

b

Black

6 (4%)

1 (2%)

Asian

29 (20%)

10 (21%)

Mixed

5 (4%)

0 (0%)

Not Response

7 (5%)

0 (0%)

Mean

31

29

Range

22 -71

23- 68

Median

27

27

Gender

Ethnicity

Race

Age (years)

Age (years)

a, Fisher exact test; b, Chi-squared test; c, Unpaired t-test
#, 1-2% of data in a group not available and was excluded in analysis.

0.6194

c#
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Characterization of cohort groups after one and four nasal swabs
The 190 individuals who enrolled in the study were predominantly of non-Hispanic
ethnicity and white race. Asian was the second most represented race while black and
mixed were least represented. The median age for both groups was 27 years and the range
of ages for each group was similar. Carriers and non-carriers identified after the first
nasal swab were well matched for gender, ethnicity, race, and age (Table 1). Within each
group, the gender breakdown was nearly half female and half male. There were no
notable differences in demographics between the two carrier groups. The 102 individuals
who completed four swabs were representative of the larger cohort that initially enrolled,
with a predominance of non-Hispanic white individuals and predominance of Asian
subjects within the non-white population. The median age for each group was similar to
that of the initial cohort. There were no notable differences between persistent carriers
and persistent non-carriers with respect to gender, ethnicity, race, and age (Table 2).

Potential risk factors for nasal carriage of S. aureus
The volunteer subjects in this study completed a questionnaire at each encounter. The
questionnaire collected information related to demographics, past medical history, use of
certain medications, and exposures potentially associated with S. aureus carriage. Since
our cohort populations were composed of healthy adults from the institution’s medical
community, we did not include questions regarding more serious medical issues that have
been associated with carriage, such as HIV, hemodialysis, and intravenous drug use.
Many of the volunteers were recruited in the clinical setting; thus we included questions
regarding patient and hospital exposures as potential factors associated with S. aureus
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TABLE 2: Characterization of cohort populations after the fourth nasal swab

Not colonized
N = 69 (68%)

Colonized
N = 33 (32%)

Male

29 (42%)

17 (52%)

Female

40 (58%)

16 (48%)

Hispanic

4 (6%)

1 (3%)

Non-Hispanic

57 (83%)

30 (91%)

No Response

8 (11%)

2 (6%)

White

44 (65%)

26 (79%)

Black

3 (4%)

1 (3%)

Asian

16 (23%)

6 (18%)

Mixed

5 (7%)

0 (0%)

No Response

1 (1%)

0 (0%)

Mean

31

30

Range

23 - 63

24 - 69

Median

28

27

P value

Gender
0.4009

a

0.5417

b

0.4111

b

Ethnicity

Race

Age (years)
Age (years)

a, Fisher exact test; b, Chi-squared test; c, Unpaired t-test
#, 1-2% of data in a group not available and was excluded in analysis.

0.5046

c#
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TABLE 3: Potential risk factors associated with S. aureus colonization of cohort
populations after the first nasal swab
Non-carriers
N = 142 (75%)

Carriers
N = 48 (25%)

0 (0%)
142 (100%)
0 (0%)

0 (0%)
47 (98%)
1 (2%)

1.0

Yes
No

11 (8%)
131 (92%)

5 (10%)
43 (90%)

0.5559

Yes
No

8 (6%)
134 (94%)

2 (4%)
46 (96%)

1.0

20 (14%)
40 (28%)
81 (57%)
1 (1%)

5 (10%)
16 (33%)
27 (57%)
0 (0%)

0.7078

13 (9%)
129 (91%)

7 (15%)
41 (85%)

0.2871

9 (6%)
133 (94%)

2 (4%)
46 (96%)

0.733

9 (6%)
133 (94%)

3 (6%)
45 (94%)

1.0

1 (1%)
3 (2%)
138 (97%)
0 (0%)

1 (2%)
0 (0%)
46 (96%)
1 (2%)

0.4337

28 (20%)
114 (80%)

7 (15%)
41(85%)

0.5215

23 (16%)
117 (82%)
2 (2%)

5 (10%)
42 (88%)
1 (2%)

0.4788

11 (8%)
128 (90%)
3 (2%)

3 (6%)
45 (94%)
0 (0%)

1.0

a#

2 (2%)
139 (97%)
1 (1%)

0 (0%)
48 (100%)
0 (0%)

1.0

a#

0 (0%)
134 (94%)
3 (2%)

1 (2%)
47 (98%)
0 (0%)

0.1266

P value

Diabetes present
Yes
No
No Response

a

Asthma present
Use tobacco
Seasonal allergies
Yes - active
Yes - not active
No allergies
No Response
Active eczema
Yes
No
Use of nasal steroids
Yes
No
Cold/URI within 10 days
Yes
No
Use of systemic steroids
Yes
Occasionally
No
No Response
Antibiotics within 6 months
Yes
No
Antibiotic ointment within 2
months
Yes
No
No Response
Use of any nasal spray
within 1 month
Yes
No
No Response
Hospitalization within 6
months
Yes
No
No Response
S. aureus infection within 6
months
Yes
No
Not sure

a

a

b#

a

a

a

b#

a

a#

b
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No Response
Children in daycare
Yes
No
No Response
Last use of public gym
>2 months
1-2 months
2-4 weeks
This week
Today
Never use
No Response
Visit to hospital within 2
weeks
Yes
No
No Response
Interact with patients as part
of studies or job
Yes
No
No Response
Type of patient interaction
Talk, no contact
Occasional contact
Repeated contact
NA
No Response
Type of patient Interaction,
binary analysis
Repeated contact
Not repeated contact
No Response

5 (4%)

0 (0%)

5 (4%)
135 (94%)
2 (2%)

5 (10%)
43 (90%)
0 (0%)

0.127

a#

35 (25%)
12 (8%)
11 (8%)
49 (35%)
5 (3%)
28 (20%)
2 (1%)

8 (17%)
5 (10%)
10 (21%)
14 (29%)
1 (2%)
10 (21%)
0

0.204

b#

92 (65%)
46 (32%)
4 (3%)

37 (77%)
11 (23%)
0

0.2061

a#

114 (80%)
26 (18%)
2 (2%)

41 (85%)
7 (15%)
0 (0%)

0.6618

a#

6 (4%)
8 (6%)
101 (71%)
25 (18%)
2 (1%)

0 (0%)
1 (2%)
40 (83%)
7 (15%)
0 (0%)

0.2766

b#

101 (71%)
39 (28%)
2 (1%)

40 (83%)
8 (17%)
0 (0%)

0.1755

a#

a, Fisher exact test; b, Chi-squared test; c, Unpaired t-test
#, 1-2% of data in a group not available and was excluded in analysis.
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colonization. Initial carrier status was identified after a single swab. There were no
statistically significant findings differentiating initial carriers and non-carriers (Table 3).
After the fourth swab, we determined which subjects were persistently colonized and
which were persistently not colonized. There were no statistically significant findings
differentiating colonized from not colonized (Table 4). There was a notable difference,
however, in the type of patient interaction between the two groups, more apparent in our
final cohort comparison. Those who were persistently culture positive for S. aureus had
an increased proportion of repeated contact with patients as opposed to no contact, just
talking, or occasional contact with patients. Comparing carriers and non-carriers of S.
aureus after a single swab, 83% versus 71% had repeated contact with patients at the
initial swab, respectively, and 85% versus 68% had repeated contact with patients as
assessed after the fourth swab, respectively.

PBMC secretion of IL-8 after stimulation with a single ligand
A total of 56 subjects donated blood samples for analysis, 21 of which were persistently
colonized and 35 were persistently not colonized. Three subjects were excluded from
cytokine analysis because of a switch in colonization status. After exclusion, the analyzed
population included 20 samples from persistently carriers and 33 samples from
persistently non-carriers. Peripheral blood monocyte cells (PBMCs) were isolated from
each subject’s blood sample and plated 106 cells/well. Cells were stimulated overnight
with one of several ligands: a synthetic bacterial lipoprotein (PAM3CSK), a diacylated
lipoprotein (FSL-1), flagellin, lipopolysaccharide (LPS), muramyl dipeptide
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TABLE 4: Potential risk factors associated with S. aureus colonization of cohort
populations after the fourth nasal swab
Not colonized
N = 69 (68%)

Colonized
N = 33 (32%)

Yes
No

0 (0%)
69 (100%)

0 (0%)
33 (100%)

1.0

Yes
No

6 (9%)
63 (91%)

4 (12%)
29 (88%)

0.7237

a

Yes
No

3 (4%)
66 (96%)

2 (6%)
31 (98%)

0.6575

a

5 (7%)
25 (36%)
39 (57%)

3 (9%)
11 (33%)
19 (58%)

0.9257

b

8 (12%)
61 (88%)

4 (12%)
29 (88%)

1.0

3 (4%)
66 (96%)

4 (12%)
29 (88%)

0.7237

7 (10%)
62 (90%)

3 (9%)
30 (91%)

1.0

a

0 (0%)
2 (3%)
67 (97%)

0 (0%)
1 (3%)
32 (97%)

1.0

a

11 (16%)
58 (84%)

4 (12%)
29 (88%)

0.7686

a

7 (10%)
62 (90%)

5 (15%)
28 (85%)

0.5179

a

5 (7%)
64 (93%)

3 (9%)
30 (91%)

0.7114

a

0 (0%)
69 (100%)

0 (0%)
33 (100%)

1.0

1 (1.5%)
62 (90%)
1 (1.5%)
5 (7%)

0 (0%)
31 (94%)
1 (2%)
1 (2%)

0.6873

4 (6%)
63 (91%)
2 (3%)

2 (6%)
31 (98%)
0 (0%)

1.0

P value

Diabetes present

a

Asthma present
Use tobacco
Seasonal allergies
Yes-active
Yes-not active
No
Active eczema
Yes
No
Use of nasal steroids
Yes
No
Cold/URI within 10 days
Yes
No
Use of systemic steroids
Yes
Occasionally
No
Antibiotics within 6 months
Yes
No
Antibiotic ointment within 2
months
Yes
No
Use of any nasal spray
within 1 month
Yes
No
Hospitalization within 6
months
Yes
No
S. aureus infection within 6
months
Yes
No
Not sure
No Response
Children in Daycare
Yes
No
No Response
Last public gym use

a

a

a

a#

b
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>2months
1-2 months
2-4 weeks
This week
Today
Never use
Visit to hospital within 2
weeks
Yes
No
Interact with patients as
part of studies or job
Yes
No
Type of patient interaction
Talk, no contact
Occasional contact
Repeated contact
NA
Type of patient Interaction,
binary analysis
Repeated contact
Not repeated contact

b

14 (20%)
4 (6%)
8 (12%)
27 (39%)
2 (3%)
14 (20%)

4 (12%)
1 (3%)
7 (21%)
11 (33%)
1 (3%)
9 (28%)

0.6565

47 (68%)
22 (32%)

22 (67%)
11 (33%)

1.0

52 (75%)
17 (25%)

27 (82%)
6 (18%)

0.6141

a

3 (4%)
2 (3%)
47 (68%)
17 (25%)

0 (0%)
0 (0%)
28 (85%)
5 (15%)

0.2434

b

47 (68%)
22 (32%)

28 (85%)
5 (15%)

0.0944

a

a, Fisher exact test; b, Chi-squared test; c, Unpaired t-test
#, 1-2% of data in a group not available and was excluded in analysis.

a
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TABLE 5: List of ligands for stimulation of PBMCs
Mechanism of action for each ligand (except S. aureus) was obtained from the InvivoGen
product information included with the purchase of the ligand.

Ligand

Innate immune system
receptor

PAM3CSK: synthetic lipoprotein

TLR-2/TLR-1

FSL-1: synthetic diacylated lipoprotein

TLR-2/TLR-6

Flagellin: purified from S. typhimurium

TLR-5

Lipopolysaccharide (LPS): from E. coli

TLR-4

Muramyl dipeptide (MDP): peptidoglycan motif

NOD 2

Lipoteichoic acid (LTA): purified from S. aureus

TLR-2

S. aureus Agr (+): wild type accessory regulator gene

TLR-2/TLR-6

S. aureus Agr (-): mutant accessory regulator gene

TLR-2/TLR-6
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(MDP), lipoteichoic acid (LTA), S. aureus with Agr (+) gene, and S. aureus with Agr (-)
mutation (Table 5). Supernatants were collected for IL-8 ELISA. PBMCs from persistent
carriers secreted less IL-8 after stimulation with each ligand compared to those cells from
persistent non-carriers (Figure 2). After stimulation with FSL-1, median IL-8 secretion was
41 ng/ml versus 61 ng/ml for colonized and not colonized samples respectively, p < 0.05
(Figure 2b). Similarly, median IL-8 secretion after stimulation with LTA (40 ng/ml versus 58
ng/ml), Agr (+) (22 ng/ml versus 60 ng/ml), and Agr (-) (29 ng/ml versus 53 ng/ml) revealed
a significant difference (p < 0.05) between persistent carrier and persistent non-carrier
samples, respectively (Figure 2b, f-h). The diminished secretion of IL-8 in response to
PAM3CSK and flagellin approached statistical significance (Figure 2a, c). With a more strict
analysis of variance using a one-way ANOVA Kruskall-Wallis test with Dunn’s Multiple
Comparisons Post-test nullified any suspected difference between the cohorts for any of the
TLR experiments (Table 6).

IL-8 secretion after PBMC sensitization
PBMCs from each subject’s blood sample were plated 106 cells/well and stimulated with
ligands as described above. Some wells that were initially stimulated with LPS or MDP
overnight were stimulated overnight for a second time with either LPS or LTA.
Supernatants were collected after the second stimulation. Cells from persistent carriers
and non-carriers that were initially stimulated with LPS had equal median secretion (0
ng/ml) after the second stimulation (Figure 3a, b), but the mean secretion revealed a
pattern in which cells from persistent carriers secreted more IL-8 after re-stimulation
compared to cells from non-carrier (Figure 3c, d). Cells from persistent carriers that were
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FIGURE 2: IL-8 secretion by PBMCs after stimulation with a single ligand
106 PBMCs from each subject were stimulated with an individual ligand: synthetic bacterial
lipoprotein (PAM 3CSK) (a), diacylated lipoprotein (FSL-1) (b), Flagellin (c),
lipopolysaccharide (LPS) (d), muramyl dipeptide (MDP) (e), lipoteichoic acid (LTA) (f), S.
aureus Agr (+) (g), S. aureus Agr (-) (h). Supernatants were collected after overnight
incubation and IL-8 ELISA was performed. Data represents quantitative box-plot analysis
(median, minimum, maximum value, 25% and 75% percentile). Comparison for
significance with two-tailed Mann-Whitney test. (*, denotes statistical significance, p < 0.05).
a)

b)
p = 0.0652

c)

e)

g)

p = 0.0552

p = 0.1498

p = 0.0188*

p = 0.0390*

d)

f)

h)

p = 0.0708

p = 0.0445*

p = 0.0348*
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TABLE 6: IL-8 secretion analysis using one-way ANOVA (KruskallWallis) with Dunn's Multiple Comparison Test

Ligand
PAM3CSK
FSL-1
Flagellin
LPS
MDP
Agr (+)
Agr (-)
LTA
LPS – LPS
LPS – LTA
MDP – LPS
MDP – LTA

Comparison
Not colonized vs. Colonized
Not colonized vs. Colonized
Not colonized vs. Colonized
Not colonized vs. Colonized
Not colonized vs. Colonized
Not colonized vs. Colonized
Not colonized vs. Colonized
Not colonized vs. Colonized
Not colonized vs. Colonized
Not colonized vs. Colonized
Not colonized vs. Colonized
Not colonized vs. Colonized

Difference P < 0.05?
in rank
sum
78.77
94.77
104.7
94.10
57.78
121.2
104.6
84.24
-21.36
-24.25
81.64
63.60

No
No
No
No
No
No
No
No
No
No
No
No
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FIGURE 3: IL-8 secretion by PBMCs after sensitization
106 PBMCs from each subject were stimulated overnight with either lipopolysaccharide
(LPS) (a and b) or muramyl dipeptide (MDP) (e and f). Supernatants were discarded and
cells were re-stimulated with either LPS (a and e) or lipoteichoic acid (LTA) (b and f).
Supernatants were collected after overnight incubation and IL-8 ELISA was performed. A, b,
e, f data represent quantitative box-plot analysis (median, minimum, maximum value,
25% and 75% percentile); c and d represent mean with SEM.

a)

p = 0.6110

b)

c)

d)

e)

f)
p = 0.0894

p = 0.8477

p = 0.1209
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initially stimulated with MDP secreted less IL-8 after the second stimulation compared to
cells from non-carriers (Figure 3d, e). This difference approached significance. It seems
that LPS and MDP have opposing effects on persistent carrier PBMCs in regards to IL-8
secretion when used to prime the cells. Priming with LPS led to an increased IL-8
response for persistent carriers, and priming with MDP led to a diminished IL-8 response
for persistent carriers after re-stimulation compared to non-carriers.

PBMC secretion of TNF-α after stimulation with a single ligand
Of the 53 subjects who donated blood and met criteria for IL-8 cytokine analysis, four
samples did not produce adequate TNF-α secretion for analysis. Thus 49 samples were
included in the TNF-α analysis. PBMCs from persistently colonized individuals secreted
less TNF-α after stimulation with each ligand compared to those cells from not colonized
individuals, except with LPS stimulation in which the two groups secreted a similar amount
(Figure 4). None of the observed differences were statistically significant, but a trend toward
significance was noted with PAM3CSK, FSL-1, LTA, Agr (+), and Agr (-) (Figure 4a-c, f-h).

TNF-α secretion after PBMC sensitization
The sensitization experiments were preformed as described above and TNF-α was
measured after re-stimulation. Cells from persistent carriers that were primed with LPS
secreted less TNF-α after re-stimulation compared to cells from non-carriers (Figure 5a,
b). This difference was statistically significant for re-stimulation with LTA after LPS
priming. Cells from persistent carriers and non-carriers that were primed with MDP
secreted similar amounts of TNF-α after re-stimulation with LPS or LTA (Figure 5c, d).
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Taking both the IL-8 and TNF-α datasets into consideration, it appears that priming cells
with LPS had an opposite effect on carrier cells depending on which cytokine was
measured. For persistent carriers, LPS priming invoked an increased IL-8 but a decreased
TNF-α response compared to non-carriers.
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FIGURE 4: TNF-α secretion by PBMCs after stimulation with a single ligand
106 PBMCs from each subject were stimulated with an individual ligand: synthetic bacterial
lipoprotein (PAM 3CSK) (a), diacylated lipoprotein (FSL-1) (b), Flagellin (c),
lipopolysaccharide (LPS) (d), muramyl dipeptide (MDP) (e), lipoteichoic acid (LTA) (f), S.
aureus Agr (+) (g), S. aureus Agr (-) (h). Supernatants were collected after overnight
incubation and TNF-α ELISA was performed. Data represents quantitative box-plot
analysis (median, minimum, maximum value, 25% and 75% percentile). Comparison for
significance with two-tailed Mann-Whitney test. (*, denotes statistical significance).
a)

c)

e)

g)

p = 0.3139

p = 0.7219

p = 0.9028

p = 0.2184

b)

d)

f)

h)

p = 0.2109

p = 0.7680

p = 0.2855

p = 0.1246
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FIGURE 3: TNF-α secretion by PBMCs after sensitization
106 PBMCs from each subject were stimulated overnight with either lipopolysaccharide
(LPS) (a and b) or muramyl dipeptide (MDP) (c and d). Supernatants were discarded and
cells were re-stimulated with either LPS (a and c) or lipoteichoic acid (LTA) (b and d).
Supernatants were collected after overnight incubation and TNF-α ELISA was performed.
Data represents quantitative box-plot analysis (median, minimum, maximum value, 25%
and 75% percentile). (*, denotes statistical significance).

a)

c)

p = 0.1146

p = 0.3043

b)

d)

p = 0.0398*

p = 0.3543
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Discussion
Epidemiology
We examined healthy adults from our academic community. This population was
amenable to volunteer in this study and maintain follow-up because of the collegial
academic environment in which they work. Despite the good will of this population, there
are limitations that result from their exclusive enrollment resulting in a selection bias.
Those people with a particular investment in the research or academic community were
preferentially targeted and enrolled, and young adults in their 20’s and 30’s were most
agreeable to participate. The generalizability of these data, therefore, is limited because
the studied population is not representative of the general, national population.
Several factors may impact the detection of S. aureus including aspects related to
methods of sample collection and methods of culturing (11). Most studies administer
nasal swabs in order to assess carriage state, but it has been reported that up to a third of
colonized states can be missed if other sites of colonization are not tested (51). We chose
to examine only the anterior nares for identification of S. aureus since it is the most
common site for colonization. We cultured the swabs on agar plates rather than in liquid
media following methods of prior studies. Our assessment of carrier status was based on
a binary evaluation of the culture using methods that indicated that the presence or
absence of S. aureus. We did not distinguish between samples that were floridly culture
positive versus samples that were found to be positive only after several steps of workup. It has been shown that evaluation of bacterial burden can distinguish different carrier
states since a low burden could be a falsely negative swab (52). It is possible that there
were false negatives in our study, but they likely would have been categorized as
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intermittent carriers; the intermittent status is most difficult to distinguish from the
persistently negative population. There is less likelihood of a false positive in our study
since we collected five swabs and included only those who had positive cultures for each
swab as persistent carriers. The positive predictive value in determining persistent
carriage status with two consecutive positive swab cultures is 79% (18); thus our positive
predictive value with five swabs was likely considerably higher. Nevertheless, it cannot
be discounted that we did not sample all sites of colonization, and we used a binary
culture analysis, both factors possibly contributing to errors in identifying our cohort
groups.
A 2009 study by van Belkum et al. outlined a strict classification of persistent
carriers and non-carriers in which participants were labeled persistent carriers if 80% of
5-10 swabs over 6 months were positive for S. aureus. They noted that allowing 1 of 5
swab samples to test negative while still categorizing a participant as persistently
colonized minimizes misclassification of carriage states from culture or lab errors (20). In
our study, there were subjects who would have fulfilled these criteria for persistent
carriage, but we did not include these subjects in our TLR experiments. It is possible,
therefore, that we unnecessarily excluded potentially revealing data from those who could
be classified as persistent carriers.
In the aforementioned study, they found that when persistent carriers, intermittent
carriers, and non-carriers were treated with mupiricon for eradication, only the persistent
carriers re-established colonization for a long stretch of time compared to the other
carriage phenotypes. It seems, therefore, that the persistent carrier phenotype is clinically
most relevant. Intermittent and non-carriers share similar colonization kinetics and pose
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less of a risk for infection (20). Our data maintain clinical relevance by strictly
identifying the persistently colonized cohort, who is at higher risk for nosocomial
infections. In order to understand the dynamics of S. aureus colonization, the multifactorial mechanisms that distinguish persistent carriers and make them so susceptible to
colonization warrant examination in future studies in order to extrapolate to a public
health domain.
In this study, we found that 25% of our subjects were carriers of S. aureus
following evaluation of a single nasal swab. This distribution was slightly lower than the
findings from other studies in which a single swab revealed 26-31% prevalence of
colonization at any given time (1). The observed decrease in prevalence, however, is in
line with the finding that colonization decreased from 2001- 2004 as evidenced by the
National Health and Nutrition Examination Survey (NHANES) (9).
Analysis of the NHANES revealed an association between healthcare exposure,
diabetes, old age and carriage of S. aureus (9). In our study, we did not find any
association between carriage and any risk factor. Our population was predominantly
young adults and did not include any diabetic participants; thus we could not adequately
evaluate for association with diabetes or old age. Regarding healthcare exposure, our data
suggest a trend in which increased patient contact is associated with persistent
colonization of S. aureus. Our study population was much smaller than that of the
NHANES. The NHANES included over 9000 participants from across the United States.
With larger cohort populations, it is possible that we would have revealed risk factors
associated with carriage. Informal analysis of our subjects who were excluded after
enrollment showed that 5 % of subjects switched their colonization status on their second
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swab (data not shown). The NHANES examined culture results from a single nasal swab,
providing information about a cross sectional sample rather than a targeted cohort as we
did when we identified persistently colonized or not colonized subjects. Our final cohort
groups were narrowed populations compared to those in the NHANES, and it is
reasonable to presume that not all associations observed in the NHANES would carry
over in our study.
The notion that the microbiome and local ecology of the anterior nares may affect
colonization is an intriguing one - the anterior nare is not a sterile environment like the
blood. Traditional theory of ecology and competition identifies organism fitness as a
determining factor for occupation of a niche or habitat. Recent studies have shown the
dynamics between skin and nasal flora to be more complicated than that. Resident
bacterial strains seem to retain a competitive advantage, possibly because of a localized
resource that serves as a limiting factor (35). Studies have also shown that recognition of
microbial products from one species may activate inflammatory responses that promote
clearance of another species (53). We did not perform experiments to assess for other
organisms within the anterior nares of our subjects, but at the blood draw encounter, we
collected an addition nasal swab that was snap frozen for future inquiries into the
microbiomes of our cohort populations. We cannot, therefore, discount the unknown
variable of the microbiome when considering the findings of our study

Sensitization
In our study, we examined PBMC sensitization. The notion of host sensitization has
been illustrated in prior studies with gram-negative organisms in which treatment with a
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non-lethal dose of LPS led to tolerance and resistance to subsequent exposures of
normally lethal doses of LPS. Pre-treatment led to an attenuation of the immune
response, preventing the physiologic decompensation that comes from a severe infection.
Murphey et al. have examined host sensitization to cell wall elements of gram-positive
bacteria. Mice were treated with a non-lethal dose of peptidoglycan (PGN) followed by
challenge with an inoculum of live S. aureus. After challenge with S. aureus, proinflammatory cytokines TNF-α and IFN-gamma were suppressed and IL-10 was
increased, which suggested a preference to a Th-2 host response after PGN priming.
Clinically, they found that pre-treatment was associated with increased bacterial
clearance and improved host survival after subsequent challenge. In another study, pretreatment with pro-inflammatory cytokine IFN-gamma enhanced release of TNF-α and
IL-8 in response to S. aureus in conjunctival epithelial cells (49). In our experiments, we
did not observe significant differences between our groups when PBMCs were primed
and re-stimulated. Some of our data suggests a potential pattern that LPS sensitizes
carrier PBMCs more effectively resulting in a less robust TNF-α response. The opposite
pattern was suggested in terms of IL-8, however, in which mean secretion from persistent
carriers was greater than that by persistent non-carriers after LPS priming. Our findings
regarding priming and sensitization remain inconclusive and further experiments are
warranted on these topics between S. aureus carriers and non-carriers.

Innate immune system
Our study is limited by the fact that we did not conduct our in vitro experiments
with epithelial cells, which are the cells in the anterior nares that would respond
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physiologically in vivo as agents of the innate immune system in response to S. aureus
exposure. Epithelial cells are a challenge to grow and maintain. We were interested in the
function of innate immune receptors; thus we made the assumption that the function of
TLRs on non-sterile epithelial cells would be comparable to the function of TLRs on
sterile peripheral blood monocytes. We also assumed the PBMCs are the same at any
given time point. These may be false assumptions. It is possible that any local
immunologic differences are attenuated at a systemic level; thus we would be missing
potential differences by not using epithelial cells. It is also possible that immune cells
obtained from a sterile environment behave significantly differently from nasal epithelial
cells. But by using our assumptions, we aimed to generalize our PBMC findings to what
might occur physiologically in the anterior nares during the complex interaction between
S. aureus and the innate immune system, a requisite interaction of microbial colonization
and one that must be addressed.
Our experiments comparing cytokine secretion by PBMCs from persistent carriers
and non-carriers included analysis with non-parametric tests. The data were not
consistently normally distributed; thus we chose a stricter non-parametric analysis for all data
rather than a parametric approach. We stimulated PBMCs with a variety of ligands without
certainty about which experiment would reveal a difference between our groups. We selected
ligands that offered some probability of revealing a difference based on literature suggesting
that S. aureus may interact with the host immune system through various pathways. The
likelihood of observing a difference between our groups increased as we increased the
number of ligands that we used. To take this into account and minimize false positives, we
performed a one-way ANOVA Kruskall-Wallis with multiple comparison Dunn’s post-test
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analysis on the IL-8 data. The Mann-Whitney tests revealed statistical significance for some
TLR experiments, but it proved to be marginal since the more conservative analysis with the
one-way ANOVA nullified the findings. A caveat to the one-way ANOVA analysis,
however, is that the chance for false negatives is increased. It is reasonable, therefore, to
consider the non-parametric (Mann-Whitney) t-test comparisons as relative findings
suggestive of a potential pattern for differences between our groups. If our sample size were
larger, it is possible we would have detected more convincing statistical significance between
our cohorts.
PBMCs from individuals who we identified as persistently colonized showed
diminished secretion of IL-8 and TNF-α in response to innate immune stimulation. Our
data do not identify a reason for this difference but do suggest some possible contributing
factors. The statistically significant differences in the non-parametric t-test IL-8 analysis
occurred with simulation by FSL-1, LTA, Agr (+) and Agr (-) strains of S. aureus. In
addition, stimulation with these ligands approached statistical significance in regards to
TNF-α secretion. These four ligands may represent an association with TLR-2.
Lipoproteins are the primary ligands of TLR-2. FSL-1, S. aureus Agr (+) and S. aureus
Agr (-) offer a source of lipoproteins. If TLR-2 were dysfunctional in cells from
persistent carriers, it may explain the diminished cytokine response. LTA, a cell surface
glycoconjugate of gram-positive bacteria is not a TLR-2 ligand, but it turns out that S.
aureus LTA preparations contain contaminants, which serve as TLR-2 activators (54).
Contaminations have resulted in several misleading conclusions about how TLR-2
functions (41). It is quite possible, therefore, that LTA itself did not contribute to the
difference we observed between carriers and non-carriers; it could have been the
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contaminants instead. Considering the notion that TLR-2 may be a factor in the
differences in cytokine secretion, it is reassuring that there was less difference in IL-8 and
TNF-α secretion between groups when cells were stimulated with MDP and LPS, known
ligands of NOD2 and TLR-4, respectively.
One might expect that triacylated lipoprotein PAM3CSK would also act through
TLR-2 and hence result in a significant diminution of IL-8 secretion by PBMCs from
persistently colonized subjects. PAM3CSK is a synthetic lipoprotein presumed to act
through the TLR-2/TLR-1 heterodimer. Recent studies have called into question the
longstanding model that triacylated lipopeptides from gram-negative bacteria stimulate
TLR2/TLR1 heteromers and that diacylated lipopeptides from gram-positive bacteria
stimulate TLR2/TLR6 heteromers. Gram-positive S. aureus lipoproteins actually exist
mainly in N-acylated triacyl forms rather than diacyl forms (47) and dimerization of
TLR-2 is not as well understood as previously thought. Kurokawa et al. have shown that
the S. aureus triacylated lipoprotein, SitC, is recognized by both TLR1/TLR2 and
TLR2/TLR6 heteromers in mouse macrophages, but it can also induce production of IL-6
and TNF-α independently of TLR-1 and TLR-6. They also have shown that SitC acts in a
TLR-2- and MyD88-dependent manner (41). It is possible, therefore, that PAM3CSK
may act in a more complicated manner than previously thought. Muller et al has found
that TLR-2 co-localizes intracellularly with SitC (55); thus TLR-2 may act both at the
intracellular and surface levels. Intracellular TLR-2 complexes are reported to be
recruited to macrophage phagosomes where they discriminate pathogens and induce proinflammatory signals for host defense (56). An increase in bacterial phagocytosis is
associated with an enhanced cytokine response (57) (58). If PAM3CSK behaved
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similarly to intracellular SitC, then it would not be affected by variations in function of
surface TLR-2.
There are three well-described functional human TLR-2 genetic polymorphisms:
Arg677Trp, Arg753Gln, and a microsatellite GT repeat in intron 2. Arg677Trp is not
present in Caucasian patients (1). It has been correlated with lepromatous leprosy and the
leprosy reversal reaction in Asian populations (59) while the Arg753Gln polymorphism
has been correlated with sepsis in white populations (60). Arg753Gln also has been
associated with mycobacterial infections, military tuberculosis, and pediatric urinary tract
infections (UTIs) (61) (62). Children carrying the allele had a higher risk of UTI with
gram positive pathogens, a higher risk of more than two previous UTIs, and a higher risk
of asymptomatic UTIs (62).
When the Arg753Gln allele is inserted into human cells, it renders the cell nonresponsive to triacylated or diacylated lipoproteins (60). From a clinical perspective,
however, some studies have found no association between the Arg753Gln allele and the
severity of S. aureus infection (63). This lack of association is consistent with in vitro
evidence that the presence of only one wild-type TLR-2 allele is required for a full
cytokine response to S. aureus (64). In counterpoint to those studies is a recent study
examining atopy. In the recent study, over 80% of subjects with atopic dermatitis were
colonized with S. aureus, and they had an increased prevalence of the Arg753Gln
polymorphism compared to a control group, 11.5% vs. 2.5% respectively. Those with
both atopic dermatitis and the polymorphism were found to have more severe atopic
disease. Those with both bronchial asthma and the polymorphism were found to have
increased levels of IgE. These data suggest that the TLR-2 polymorphism Arg753Gln
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may increase the susceptibility to infections and chronic colonization (65). If we were to
develop a hypothesis for further inquiry into our observed differences in cytokine
production between persistent carriers and non-carriers, an assessment of TLR-2
polymorphisms would be a reasonable and interesting avenue of exploration.
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SUPPLEMENTAL FIGURE 1: Assessing for presence of S. aureus from nasal swab
culture
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SUPPLEMENTAL MATERIAL: Questionnaire administered to each subject at
each encounter
I. DEMOGRAPHICS:
1. GENDER:

Male

2. ETHNICITY:

Hispanic or Latino

3. RACE:

Female
Not Hispanic or Latino

American Indian/Alaska Native

Asian

White

Black or African American

Native Hawaiian/Other Pacific

Islander
4. DATE OF BIRTH (MM/DD/YYYY): ____/____/____
II. Health related risks for S. aureus colonization. Please circle Yes , No or NA (not
applicable) for each question.
1. Do you have diabetes mellitus?

Yes

No

If you are diabetic, what has your AM fingerstick glucose been over the last week?
<110
NA

110-180

180-250

>250

2. Do you have asthma?

Yes

No

3. Do you smoke tobacco?

Yes

No

4. Do you have seasonal allergies?
No

Yes/Currently active

5. Do you have active eczema or atopic dermatitis?
6. Do you use nasal steroids?

don’t know

Yes/not active

Yes

Yes

No
No

7. Did you have a cold or upper respiratory tract infection in the last 10 days?
No
8. Do you use systemic steroids, such as prednisone?
Occasionally

Yes

Yes

No

9. If you take pulse-dose or intermittent steroids, when was your last dose?

NA

66
Today
>6mos

This week

Last 2-4 weeks

1-2 months ago

2-6 months

10. Have you taken antibiotics (pills or intravenous) in the last 6 months?
No
If yes, when was your most recent antibiotic dose?
Today

This week

Last 2-4 weeks

Yes

NA

1-2 months ago

2-6 months

Do you remember the name of the most recent antibiotic? If yes, please
list:_______________
11. Have you used an antibiotic cream or ointment in the last 2 months?
No
When was your most recent use?
Today

This week

Yes

NA

Last 2-4 weeks

1-2 months ago

12. Do you use medications other than prednisone that might suppress your immune
system?
Yes

No

Not sure whether _________________________ counts

13. Have you used any sort of nasal spray in the last month?

Yes

No

14. Have you been hospitalized within the last 6 months?

Yes

No

If so, when:
months ago

Last week

Last month

2 months ago

15. Were you treated for a S. aureus infection in the last 6 months?
Not sure

2-6
Yes

No

III. Exposure related risks for S. aureus colonization.
1. Do you have any children in day care?

Yes

2. When did you last use a public gym facility?

NA, I never do this.

Today

This week

2-4 weeks ago

No

1-2 months ago

>2 months

3. Have you been to a hospital, nursing home, or rehab center in the last 2 weeks?
Yes
No
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4. Do you interact with patients as part of your studies or job?
No

Yes

If you interact with patients, please pick the description that best fits your
exposure:
NA
Talk, but minimal physical contact (bedside interview)
Talk, plus occasional physical contact with patient (assist with transfer, check vitals)
Talk plus repeated physical contact, i.e. patient physical exam or patient care
If you have examined patients or taken part in their care in the last month, please
indicate in what health care setting(s)? NA
Outpatient clinic
Surgical Floor
Operating Room

Emergency Room
Non-surgical Inpatient Floor

Inpatient Psychiatry Ward
Intensive Care

